Clinical analysis of 16 cases of adult acute B-lymphoblastic leukemia treated with blinatumomab
10.3760/cma.j.cn121090-20240611-00219
- VernacularTitle:贝林妥欧单抗治疗成人急性B淋巴细胞白血病16例临床分析
- Author:
Zhiyin LIU
1
;
Sujiang ZHANG
1
;
Zeying YAN
1
;
Haimin SUN
1
;
Yubao CHEN
1
Author Information
1. 上海交通大学医学院附属瑞金医院血液科，上海 201800
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2025;46(3):269-272
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to investigate the efficacy and safety of blinatumomab in adult patients with acute B-lymphoblastic leukemia (B-ALL) by conducting a retrospective analysis of the clinical data from 16 patients with B-ALL receiving blinatumomab at the Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, from June 2022 to April 2024. Among the 16 patients, 10 were classified as relapsed/refractory B-ALL and 6 were newly diagnosed Ph - B-ALL. Of the 10 patients with relapsed/refractory B-ALL, 8 achieved complete remission (CR) and minimal residual disease (MRD) negativity after one blinatumomab treatment cycle. In the 6 newly diagnosed patients, the bone marrow MRD was negative after one blinatumomab treatment cycle after initial induction chemotherapy followed by sequential blinatumomab treatment. Among them, four completed allogeneic hematopoietic stem cell transplantation and continuously maintained CR. This indicates that blinatumomab exhibits a high remission rate in both patients with relapsed/refractory and newly diagnosed B-ALL, thereby providing the possibility of bridging to transplantation and extending patient survival, with manageable adverse reactions.
